The Ch14.18-GM-CSF fusion protein is effective at mediating antibody- dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 4259-4263

  Batova, Ayse ^a   Kamps, Arvid ^b   Gillies, Stephen D ^c   Reisfeld, Ralph A ^d   Yu, Alice L ^a,e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b HOSPITAL DE WEEZENLANDEN   (Netherlands)

^c Fuji ImmunoPharmaceuticals Corp   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CELL KILLING; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFECT; EFFECTOR CELL; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; MONONUCLEAR CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; GANGLIOSIDES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GRANULOCYTES; HUMANS; IMMUNOCONJUGATES; LEUKOCYTES, MONONUCLEAR; MICE; NEUROBLASTOMA; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0033373265     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. D2 specific monoclonal antibodies. Nucl. Med. Biol., 16: 111-120, 1989.
2. Kemshead, J. T., Fritschy, J., Goldman, A., Malpas, J. S., and Pritchard, J. Use of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic disorders. Lancet, 1: 12-14, 1983.
3. D2 in tumor tissue and sera of neuroblastoma patients. Cancer Res., 44: 5914-5920, 1984.
4. Reisfeld, R. A., and Cheresh, D. A. Human tumor antigens. Adv. Immunol., 40: 323-377, 1987.
5. D2: in vivo reactivity. Proc. Am. Assoc. Cancer Res., 25: 248, 1984.
6. Gillies, S. D., Lo, K-M., and Wesolowski, J. High level expression of chimeric antibodies using adapted cDNA variable region cassettes. J. Immunol. Methods, 125: 191-202, 1989.
7. D2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res., 51: 144-149, 1991.
8. D2 antibody. J. Immunol., 144: 1382-1386, 1990.
9. Yu, A. L., Uttenreuther, M. M., Huang, C-S., Reisfeld, R. A., and Kung, F. Phase I trial of a human-mouse chimeric anti-disialoganglioside (GD2) monoclonal antibody Ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol., 16: 2169-2180, 1998.
10. Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., Reuland, P., Gillies, S. D., Reisfeld, R. A., and Neithammer, D. A Phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur. J. Cancer, 31A: 261-267, 1995.
11. Liesveld, J. L., Frediani, D. E., Winslow, J. M., Duerst, R. E., and Abboud, C. N. Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. J. Cell. Biochem., 45: 381-390, 1991.
12. Erbe, D. V., Collins, J. E., Shen, L., Graziano, R. F., and Fanger, M. W. The effect of cytokines on the expression and function of Fc receptors for IgG on human myeloid cells. Mol. Immunol., 27: 57-67, 1990.
13. Lichtenstein, A. Granulocytes as possible effectors of tumor immunity. Hum. Cancer Immunol., 10: 731, 1990.
14. Kushner, B. H., and Cheung, N. K. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood, 73: 1936-1941, 1989.
15. Yu, A. L., Uttenreuther, M. M., Kamps, A., Batova, A., and Reisfeld, R. A. Combined use of a human-mouse chimeric anti-GD2 (ch14.18) and GM-CSF in the treatment of refractory neuroblastoma. Antibody Immunoconjugates Radiopharmaceuticals, 8: 12, 1995.
16. Ragnhammar, P., Masucci, G., Frodin, J. E., Hjelm, A. L., and Mellstedt, H. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony stimulating factor. Cancer Immunol. Immunother., 35: 158-164, 1992.
17. Mellstedt, H., Frodin, J. E., Ragnhammar, P., Masucci, G., Ljungberg, A., Hjelm, A. L., Fagerberg, J., Lindemalm, C., Osterborg, A., and Wersall, P. Therapy of colorectal carcinoma with monoclonal antibodies (Mab17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol., 30: 923-931, 1991.
18. Yu, A. L., Batova, A., Alvarado, C., Rao, V. J., and Castelberry, R. P. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study. Proc. Am. Soc. Clin. Oncol., 16: 1846, 1997.
19. Gillies, S. D., Young, D., Lo, K-M., and Roberts, S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjugate Chem., 4: 230-235, 1993.
20. Gillies, S. D., Young, D., Lo, K-M., Foley, S. F., and Reisfeld, R. A. Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Hybridoma, 10: 347-356, 1991.
21. Gillies, S. D., Reilly, E. B., Lo, K-M., and Reisfeld, R. A. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA, 89: 1428-1432, 1992.
22. Pross, H. F., Baines, M. G., and Rubin, P. Spontaneous human lymphocyte mediated cytotoxicity against tumor target cell. IX. The quantitation of natural killer cell activity. J. Clin. Immunol., 1: 51-63, 1981.
23. Rosenblum, M. G., Cheung, L., Murray, J. L., and Bartholomew, R. Antibody-mediated delivery of tumor necrosis factor (TNF-α): improvement of cytotoxicity and reduction of cellular resistance. Cancer Commun., 3: 21-27, 1991.
24. Bill, A. H. Immune aspects of neuroblastoma. Current information. Am. J. Surg., 122: 142-147, 1971.
25. Floutsis, G., Ulsh, L., and Ladisch, S. Immunosuppressive activity of human neuroblastoma tumor gangliosides. Int. J. Cancer, 43: 6-9, 1989.
26. Gasson, J. C., Weisbart, R. H., Kaufman, S. E., Clark, S. C., Hewick, R. M., Wong, G. G., and Golde, D. W. Purified human granulocyte-macrophage colony stimulating factor: direct action on neutrophils. Science (Washington DC), 226: 1339-1342, 1984.
27. Tseng, S. H., Hsieh, C. L., Lin, S. M., and Hwang, L. H. Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain. Cancer Gene Ther., 6: 302-312, 1999.
28. Becker, J. C., Pancook, J. D., Gillies, S. D., Furakawa, K., and Reisfeld, R. A. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin-2 therapy. J. Exp. Med., 183: 2361-2366, 1996.
29. Lode, H. N., Xiang, R., Varki, N. M., Dolman, C. S., Gillies, S. D., and Reisfeld, R. A. Targeted interleukin-2 therapy of spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst., 89: 1586-1594, 1997.
30. LeBerthon, B., Khawli, L. A., Alauddin, M., Miller, G. K., Charak, B. S., Mazumder, A., and Epstein, A. L. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res., 51: 2694-2698, 1991.
31. Robert, B., Mach, J-P., Mani, J-C., Ychou, M., Follie, S., Artus, J-C., and Pelegrin, A. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor α. Cancer Res., 56: 4758-4765, 1996.
32. Pervin, S., Chakraborty, M., Bhattacharya-Chatterjee, M., Zeytin, H., Foon, K. A., and Chatterjee, S. K. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen. Cancer Res., 57: 728-734.
33. Herlyn, D., Wettendorff, M., Schmoll, E., Iliopoulos, D., Schedel, I., Dreikhausen, U., Raab, R., Ross, A. H., Jaksche, H., Scriba, M., and Koprowski, H. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc. Natl. Acad. Sci. USA, 84: 8055-8059, 1987.